Sumit Bilgaiyan
Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical organization. It has 16 manufacturing facilities across
five countries and has six R&D centers. Its Generics business services the requirements of the US and Western European markets and the API
business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.
Company has posted good numbers for Q2FY19. During Q2FY19, its net profit increased by 93.32 percent to Rs 414 crore from Rs 214.12 crore on YoY basis on 14.23 percent higher sales of Rs 2539.86 crore. EBITDA grew by 13.3 percent in Q2FY19 to Rs 440.11 crore. It’s PAT increased by 18.17 percent to Rs 646.99 crore in H1FY19. FIIs and DIIs have increased their stake during Q2FY19.
We are recommending a buy in staggered manner for medium to long term.
Disclaimer: The views and investment tips expressed by investment expert on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
